Could Blockchain Ensure Integrity of Clinical Trial Data?

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable audit trail that makes it easy to spot any tampering with results - such as making the treatment look more effective or diminishing side effects.

"Everyone is talking about how blockchain is going to revolutionize many of the data challenges in medicine, and here is one use that finally might make sense," said Atul Butte, MD, PhD, who is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and director of the Bakar Computational Health Sciences Institute at UCSF. "We think it could someday be useful for pharma companies running clinical trials."

The research was published February 22 in Nature Communications.

Blockchain technology utilizes an old computer science technique known as hashing, which creates a unique digital signature for each so-called block of data. The hashes accumulate sequentially, as new data is entered or changed, with each block depending on the last. The resulting "blockchain" creates an audit trail for regulators that is easy to decipher and validate, even without looking at the actual data.

Daniel Wong, a PhD candidate in Biological and Medical Informatics at UCSF, built the system to operate through a web portal, so that each time new data is entered on a given trial participant, the sender, receiver, timestamp, and file attachment containing the data, along with the hash of the previous block of data pertaining to that patient, is recorded onto a new block, with its own distinct signature.

Unlike the decentralized nature of most blockchain applications, this clinical trial prototype depends on having a regulator with centralized authority, such as the U.S. Food and Drug Administration, to operate the web portal, register all parties, and keep a ledger of the blockchain's hashes.

Data, including adverse events, would be reported to the regulatory agency in real time, which may provide a boost to the safety and efficiency of clinical trials. While the prototype makes allowances for data entry or other errors to be corrected, new data can only be appended to the existing chain, without erasing what was there before.

"It makes it really obvious when someone's changing something," Wong said. "You can see who put their hands on it, who made it, who changed it, and who received it."

Wong tested the system with a small subset of data from a real, previously run phase II trial included in ImmPort, a repository of open clinical trial data funded by the National Institutes of Allergy and Infectious Diseases (NIAID) that is managed by Butte's lab and collaborators.

After entering the original data, he logged in as the trial sponsor and tried to erase adverse events that had been reported for two patients in their case report forms. Instead of deleting those reports, however, the system appended his changes to the original data, making it clear who had tried to corrupt the forms, when it was done, and what had been changed.

Wong also tried corrupting the data stored from an earlier point in the trial, when patients were assigned to different treatment arms -- drug or placebo -- to make it look as though they had been given a different medication plan. But the blockchain ledger pinpointed exactly what had changed and when.

A prototype system like this reduces risks, but does not completely protect data from tampering. Even within a system enabled with this type of blockchain technology, the authors pointed out, it is still possible that those seeing patients at the point of care could enter wrong or incorrect data at the outset.

But blockchain technology could enable trials to be conducted under challenging conditions, or open doors to data exchanges that are more secure, more efficient, and more transparent for both researchers and the general public.

"A system built upon our prototype could be developed to enable oversight of international clinical trials, for example," Butte said. "And it could be expanded to provide more access to raw data for research scientists, the way we do with ImmPort, or deliver trial results to the public."

Daniel R Wong, Sanchita Bhattacharya, Atul J Butte.
Prototype of running clinical trials in an untrustworthy environment using blockchain.
Nature Communicationsvolume 10, Article number: 917 2019. doi: 10.1038/s41467-019-08874-y.

Most Popular Now

Novartis and Microsoft Announce Collabor…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The...

Guerbet and IBM Watson Health Announce a…

Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, announced that it has signed a new agreement with IBM Watson Health to co-develop and...

Bayer Inks Deals with Eleven Startups un…

Bayer announced today that the company has signed collaboration agreements with eleven digital health startups. As part of the program, Bayer will support these startup companies aiming for longer-term collaborations...

Orion Health Delivers the First Health I…

The first Health Information Exchange (HIE) in the Middle East, Malaffi, went live at the end of July just six months after contracts were signed between the project company, Abu...

Joined Up Health and Care 2019 to Explor…

Professionals from across the country will come together to seek real answers on how to deliver closely integrated services, as the Joined Up Health and Care conference returns for its...

IMS MAXIMS Wins Healthcare Innovation Aw…

Health technology specialist IMS MAXIMS has been recognised for its innovative work in the UK and Irish healthcare market in the 2019 CV Business Innovator Awards. The company has been...

Health Tech Marketing and PR Agency Incr…

Highland Marketing, a full service agency for health techmarketing, PR and communications, has appointed Tia Dissanayake to a new account executive role,in which she will support the team withher life...

Brain-Computer Interfaces without the Me…

It sounds like science fiction: controlling electronic devices with brain waves. But researchers have developed a new type of electroencephalogram (EEG) electrode that can do just that, without the sticky...

Up-Close and Personal with Neuronal Netw…

How our brain cells, or neurons, use electrical signals to communicate and coordinate for higher brain function is one of the biggest questions in all of science. For decades, researchers...

Almirall Takes a Leap into Dermatology D…

Almirall, S.A. (ALM) has launched its first call for innovation to start-ups focused on dermatology digital health. This initiative is the first step in the creation of an accelerator programme...